Novo Nordisk buys production plant in New Hampshire

Novo Nordisk's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Bagsværd, Denmark, 27 August 2014 - Novo Nordisk today announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech.

The facility was established in 1989, expanded in 2003-2006 and acquired by Olympus Biotech in 2011. It has been used primarily for mammalian cell manufacturing until production was phased out earlier this year.

Novo Nordisk intends to use the facility for production of active pharmaceutical ingredients primarily for its portfolio of biopharmaceuticals. Some of the plant's former employees have been offered jobs, which initially will focus on planning of the future plant setup. Final plans will determine potential and timing for future staffing increases.

Novo Nordisk and Olympus Biotech have agreed not to disclose the terms of the acquisition.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com.

News Source : Novo Nordisk buys production plant in New Hampshire
Copy this html code to your website/blog to embed this press release.